1	3 male and female patient will be eligible for enrollment female should be either of nonchildbearing potential a a result of surgery or menopause 1 year after onset or of childbearing potential and practice a medically acceptable method of contraception e.g. abstinence a barrier method plus spermicide|spermicide[292,302]||||||||||9969|9969|spermicide
2	or intrauterine device iud for at least 1 month before visit 1 screening and for 1 month after the end of the study they must also have a negative serum beta-human chorionic gonadotropin b-hcg at screening those females use hormonal contraceptive must also be use an additional approved method of|hcg[492,495]||intrauterine device[306,325]|||||1 month[343,350]||C1141639|340705|340705|chorionic gonadotropin, human
3	contraception e.g. a barrier method plus spermicide or iud starting with the baseline phase and continue throughout the entire study period|spermicide[641,651]||||||||||9969|9969|spermicide
